Last reviewed · How we verify
HBsAg
HBsAg is a hepatitis B surface antigen used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection.
HBsAg is a hepatitis B surface antigen used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals.
At a glance
| Generic name | HBsAg |
|---|---|
| Also known as | hepatitis B vaccine based on hepatitis B surface antigen |
| Sponsor | Vaxine Pty Ltd |
| Drug class | Vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
HBsAg functions as a vaccine antigen by presenting the hepatitis B surface protein to the immune system, triggering both humoral (antibody) and cellular immune responses. This leads to the production of anti-HBs antibodies that provide protection against hepatitis B virus infection. The antigen is typically derived from recombinant DNA technology or plasma-derived sources.
Approved indications
- Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (PHASE1)
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- HepB mAb19 in Individuals With Chronic Hepatitis B Infection (PHASE1)
- Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. (PHASE4)
- Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |